FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890733033> ?p ?o ?g. }

• W2890733033 endingPage "S32" @default.
• W2890733033 startingPage "S31" @default.
• W2890733033 abstract "IntroductionAG10 is a novel, potent and selective oral transthyretin (TTR) stabilizer under clinical development to treat TTR amyloidosis (ATTR). Both mutant and wild-type ATTR are under-diagnosed diseases with no FDA-approved therapies. As ATTR is caused by the destabilization of TTR tetramers due to inherited mutations or aging, AG10 is designed to treat the disease at its source.HypothesisAG10 is safe and well tolerated at exposures reaching target therapeutic plasma concentrations, resulting in complete stabilization of TTR following repeat dosing in healthy volunteers (HV), and predicting clinical efficacy in treating both mutant and wild-type ATTR.MethodsSingle and multiple ascending oral doses of AG10 were administered in a double blind manner to 4 single and 3 multiple dose cohorts consisting of 8 HV per cohort randomized 3:1 (AG10: placebo). Safety and tolerability were assessed by vital signs, ECG, adverse events, and safety labs to monitor kidney and liver function, electrolytes, and hematology. Pharmacokinetics were measured using a validated bioanalytical assay. Pharmacodynamics (PD) were assessed via two established ex vivo assays for TTR stabilization, fluorescent probe exclusion and Western blot.ResultsSingle oral doses of 50, 150, 300 and 800 mg, and multiple oral doses to steady state of 100, 300 and 800 mg q12h were well tolerated with a clean safety profile. AG10 was rapidly absorbed with tmax <1 hr. Both Cmax and AUC were dose-dependent, terminal t1/2 was ∼25 hr, and there was little food effect (slightly increased Tmax, blunted Cmax, and 11% increase in AUC following a high fat meal). The PD profile, as assessed by either assay, demonstrated complete stabilization of TTR at Cmax following single doses of 300 mg or more, and >95% stabilization on average across the entire dosing interval of 800 mg q12h at steady state with low inter-subject variability (Figure).ConclusionsAG10, a novel, potent and selective oral TTR stabilizer, is safe and well-tolerated following oral dosing in healthy volunteers and completely stabilizes TTR (>90%) across the dosing interval, establishing clinical proof of concept. Based on these data, AG10 has the potential to be a safe and effective treatment for patients with ATTR. AG10 is a novel, potent and selective oral transthyretin (TTR) stabilizer under clinical development to treat TTR amyloidosis (ATTR). Both mutant and wild-type ATTR are under-diagnosed diseases with no FDA-approved therapies. As ATTR is caused by the destabilization of TTR tetramers due to inherited mutations or aging, AG10 is designed to treat the disease at its source. AG10 is safe and well tolerated at exposures reaching target therapeutic plasma concentrations, resulting in complete stabilization of TTR following repeat dosing in healthy volunteers (HV), and predicting clinical efficacy in treating both mutant and wild-type ATTR. Single and multiple ascending oral doses of AG10 were administered in a double blind manner to 4 single and 3 multiple dose cohorts consisting of 8 HV per cohort randomized 3:1 (AG10: placebo). Safety and tolerability were assessed by vital signs, ECG, adverse events, and safety labs to monitor kidney and liver function, electrolytes, and hematology. Pharmacokinetics were measured using a validated bioanalytical assay. Pharmacodynamics (PD) were assessed via two established ex vivo assays for TTR stabilization, fluorescent probe exclusion and Western blot. Single oral doses of 50, 150, 300 and 800 mg, and multiple oral doses to steady state of 100, 300 and 800 mg q12h were well tolerated with a clean safety profile. AG10 was rapidly absorbed with tmax <1 hr. Both Cmax and AUC were dose-dependent, terminal t1/2 was ∼25 hr, and there was little food effect (slightly increased Tmax, blunted Cmax, and 11% increase in AUC following a high fat meal). The PD profile, as assessed by either assay, demonstrated complete stabilization of TTR at Cmax following single doses of 300 mg or more, and >95% stabilization on average across the entire dosing interval of 800 mg q12h at steady state with low inter-subject variability (Figure). AG10, a novel, potent and selective oral TTR stabilizer, is safe and well-tolerated following oral dosing in healthy volunteers and completely stabilizes TTR (>90%) across the dosing interval, establishing clinical proof of concept. Based on these data, AG10 has the potential to be a safe and effective treatment for patients with ATTR." @default.
• W2890733033 created "2018-09-27" @default.
• W2890733033 creator A5015018500 @default.
• W2890733033 creator A5023698516 @default.
• W2890733033 creator A5024090042 @default.
• W2890733033 creator A5043286608 @default.
• W2890733033 creator A5043605764 @default.
• W2890733033 creator A5063362950 @default.
• W2890733033 creator A5084300737 @default.
• W2890733033 creator A5087726605 @default.
• W2890733033 date "2018-08-01" @default.
• W2890733033 modified "2023-09-25" @default.
• W2890733033 title "AG10, A Novel, Potent and Selective Transthyretin Stabilizer, is Well Tolerated at Doses Resulting in Target Therapeutic Blood Levels, and Demonstrates Clinical Proof-of-Concept in Healthy Volunteers" @default.
• W2890733033 doi "https://doi.org/10.1016/j.cardfail.2018.07.091" @default.
• W2890733033 hasPublicationYear "2018" @default.
• W2890733033 type Work @default.
• W2890733033 sameAs 2890733033 @default.
• W2890733033 citedByCount "3" @default.
• W2890733033 countsByYear W28907330332019 @default.
• W2890733033 countsByYear W28907330332020 @default.
• W2890733033 crossrefType "journal-article" @default.
• W2890733033 hasAuthorship W2890733033A5015018500 @default.
• W2890733033 hasAuthorship W2890733033A5023698516 @default.
• W2890733033 hasAuthorship W2890733033A5024090042 @default.
• W2890733033 hasAuthorship W2890733033A5043286608 @default.
• W2890733033 hasAuthorship W2890733033A5043605764 @default.
• W2890733033 hasAuthorship W2890733033A5063362950 @default.
• W2890733033 hasAuthorship W2890733033A5084300737 @default.
• W2890733033 hasAuthorship W2890733033A5087726605 @default.
• W2890733033 hasBestOaLocation W28907330331 @default.
• W2890733033 hasConcept C111113717 @default.
• W2890733033 hasConcept C112705442 @default.
• W2890733033 hasConcept C121157162 @default.
• W2890733033 hasConcept C126322002 @default.
• W2890733033 hasConcept C197934379 @default.
• W2890733033 hasConcept C22979827 @default.
• W2890733033 hasConcept C2777288759 @default.
• W2890733033 hasConcept C2778375690 @default.
• W2890733033 hasConcept C71924100 @default.
• W2890733033 hasConcept C76318530 @default.
• W2890733033 hasConcept C90924648 @default.
• W2890733033 hasConcept C98274493 @default.
• W2890733033 hasConceptScore W2890733033C111113717 @default.
• W2890733033 hasConceptScore W2890733033C112705442 @default.
• W2890733033 hasConceptScore W2890733033C121157162 @default.
• W2890733033 hasConceptScore W2890733033C126322002 @default.
• W2890733033 hasConceptScore W2890733033C197934379 @default.
• W2890733033 hasConceptScore W2890733033C22979827 @default.
• W2890733033 hasConceptScore W2890733033C2777288759 @default.
• W2890733033 hasConceptScore W2890733033C2778375690 @default.
• W2890733033 hasConceptScore W2890733033C71924100 @default.
• W2890733033 hasConceptScore W2890733033C76318530 @default.
• W2890733033 hasConceptScore W2890733033C90924648 @default.
• W2890733033 hasConceptScore W2890733033C98274493 @default.
• W2890733033 hasIssue "8" @default.
• W2890733033 hasLocation W28907330331 @default.
• W2890733033 hasOpenAccess W2890733033 @default.
• W2890733033 hasPrimaryLocation W28907330331 @default.
• W2890733033 hasRelatedWork W1541103017 @default.
• W2890733033 hasRelatedWork W1822154343 @default.
• W2890733033 hasRelatedWork W2091460425 @default.
• W2890733033 hasRelatedWork W2479254611 @default.
• W2890733033 hasRelatedWork W2626992247 @default.
• W2890733033 hasRelatedWork W2899652252 @default.
• W2890733033 hasRelatedWork W2922882148 @default.
• W2890733033 hasRelatedWork W3146022116 @default.
• W2890733033 hasRelatedWork W3207313530 @default.
• W2890733033 hasRelatedWork W3217284656 @default.
• W2890733033 hasVolume "24" @default.
• W2890733033 isParatext "false" @default.
• W2890733033 isRetracted "false" @default.
• W2890733033 magId "2890733033" @default.
• W2890733033 workType "article" @default.